Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks

• Published in: European journal of nuclear medicine and molecular imaging Vol. 47; no. 3; pp. 713 - 720
• Main Authors: Rasul, Sazan, Hacker, Marcus, Kretschmer-Chott, Elisabeth, Leisser, Asha, Grubmüller, Bernhard, Kramer, Gero, Shariat, Shahrokh, Wadsak, Wolfgang, Mitterhauser, Markus, Hartenbach, Markus, Haug, Alexander R.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.03.2020; Springer Nature B.V
• Subjects: Anemia; Cardiology; Castration; Hemoglobin; Imaging; Intervals; Leukocytes; Leukopenia; Lutetium isotopes; Medicine; Medicine & Public Health; Metastases; Metastasis; Nuclear Medicine; Oncology; Oncology – Genitourinary; Original; Original Article; Orthopedics; Patients; Platelets; Prostate cancer; Radiology; Receiving; Reduction; Statistical models; Survival; Therapy; Toxicity; mCRPC; PSMA PET; PSMA therapy; Prostate cancer; PSA response

Purpose [ 177 Lu]Lu-PSMA-617 radio-ligand therapy (PSMA-RLT) is emerging in patients with an advanced metastatic castration-resistant prostate cancer (mCRPC). Here, we aimed to estimate the results of PSMA-RLT in terms of response, progression-free survival (PFS), and overall survival (OS) in patien...